Sassene P J, Michaelsen M H, Mosgaard M D, Jensen M K, Van Den Broek E, Wasan K M, Mu H, Rades T, Müllertz A
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen , Universitetsparken 2, Copenhagen 2100, Denmark.
Faculty of Pharmaceutical Sciences, University of British Columbia , 2146 East Mall, Vancouver, BC V6T 1Z3, Canada.
Mol Pharm. 2016 Oct 3;13(10):3417-3426. doi: 10.1021/acs.molpharmaceut.6b00413. Epub 2016 Aug 30.
Precipitation of poorly water-soluble drugs from lipid-based drug delivery systems (LbDDS) has been studied extensively during in vitro lipolysis but has never been shown in vivo. The aim of this study was therefore to investigate if drug precipitation can occur from LbDDS during transit of the gastrointestinal tract in vivo. Rats were administered 300 μL of either of two LbDDS (LbDDS I and LbDDS II) loaded with danazol or fenofibrate (or paracetamol to assess gastric emptying). The rats were euthanized at various time points after administration of both LbDDS containing either drug, and the contents of the stomach and proximal part of the small intestine were harvested. The contents were analyzed for crystalline drug by X-ray powder diffraction and polarized light microscopy. No drug precipitation was evident in the stomach or the intestine after administration of LbDDS I containing danazol at the tested time points. Fenofibrate precipitation was absent in the stomach initially after administration of LbDDS I, but was evident in the stomach 90 min after dosing. No crystalline fenofibrate was observed in the intestine. Danazol and fenofibrate precipitation was evident in the stomach following administration of LbDDS II containing either drug, but not in the intestine at the tested time point. Drug precipitation from LbDDS was observed in the stomach, but not in the intestine, which is contrary to what in vitro lipolysis data (obtained under human GI conditions) suggests. Thus, precipitation of drugs from LbDDS in vivo in rats is much lower than might be anticipated from in vitro lipolysis data.
在体外脂解过程中,对难溶性药物从脂质体药物递送系统(LbDDS)中的沉淀现象已进行了广泛研究,但尚未在体内得到证实。因此,本研究的目的是调查在体内胃肠道转运过程中,LbDDS是否会发生药物沉淀。给大鼠分别灌胃300μL两种载有达那唑或非诺贝特(或对乙酰氨基酚以评估胃排空情况)的LbDDS(LbDDS I和LbDDS II)。在给予含上述两种药物的LbDDS后,于不同时间点处死大鼠,并收集胃和小肠近端内容物。通过X射线粉末衍射和偏光显微镜分析内容物中的结晶药物。在测试时间点给予含达那唑的LbDDS I后,胃或肠道中均未发现明显的药物沉淀。给予LbDDS I后,最初胃中未出现非诺贝特沉淀,但给药90分钟后胃中出现明显沉淀。肠道中未观察到结晶状非诺贝特。给予含上述两种药物的LbDDS II后,胃中出现达那唑和非诺贝特沉淀,但在测试时间点肠道中未出现。观察到LbDDS中的药物在胃中沉淀,但在肠道中未沉淀,这与体外脂解数据(在人体胃肠道条件下获得)所显示的情况相反。因此,大鼠体内LbDDS中药物的沉淀比体外脂解数据预期的要低得多。